A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

Summary

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Biological
  Amivantamab

  Amivantamab will be administered.

• Biological
  Cetuximab

  Cetuximab will be administered.

• Biological
  Bevacizumab

  Bevacizumab will be administered.

• Drug
  5-fluorouracil

  5-fluorouracil will be administered as chemotherapy regimen.

• Drug
  Leucovorin calcium/Levoleucovorin

  Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.

• Drug
  Irinotecan

  Irinotecan will be administered as chemotherapy regimen.

Locations (241)